Search results for " HEP"

showing 8 items of 2648 documents

Influencia del tratamiento radiológico locorregional pretrasplante en la evolución de los pacientes trasplantados por cirrosis hepática con carcinoma…

2015

El carcinoma hepatocelular (CHC) es el tumor maligno hepático primario más frecuente y representa la tercera causa de cáncer en el mundo. Su incidencia está aumentando considerablemente en las últimas décadas1. Este tumor se desarrolla habitualmente sobre hígados cirróticos y la resección quirúrgica sólo es posible en menos del 30% de los casos2. El trasplante hepático (TH) es el único tratamiento potencialmente curativo y su realización en pacientes con carcinoma hepatocelular que cumplen criterios de Milán3 está plenamente aceptado4, avalado por sus buenos resultados a largo plazo5,6. Cuando se cumplen estos criterios, la tasa de supervivencia a los 5 años después del trasplante es del 70…

trasplante hepáticoUNESCO::CIENCIAS MÉDICAStratamiento radiológico locorregional:CIENCIAS MÉDICAS [UNESCO]Carcinoma hepatocelular
researchProduct

Survival trends for primary liver cancer, 1995–2009: analysis of individual data for 578,740 patients from 187 population-based registries in 36 coun…

2019

CONCORD Working Group Members: Africa—Algeria: S Bouzbid (Registre du Cancer d’Annaba); M Hamdi-Chérif*, Z Zaidi (Registre du Cancer de Sétif); Gambia: R Swaminathan (National Cancer Registry); Lesotho: SH Nortje (Children’s Haematology Oncology Clinics - Lesotho); Libya: MM El Mistiri (Benghazi Cancer Registry); Mali: S Bayo, B Malle (Kankou Moussa University); Mauritius: SS Manraj, R Sewpaul-Sungkur (Mauritius National Cancer Registry); Nigeria: A Fabowale, OJ Ogunbiyi* (Ibadan Cancer Registry); South Africa: D Bradshaw, NIM Somdyala (Eastern Cape Province Cancer Registry); DC Stefan (Umtata University); Tunisia: L Jaidane, M Mokni (Registre du Cancer du Centre Tunisien).
America (Central…

trendsFunnel plotmedicine.medical_specialtySurvivalPopulationPsychological interventionSocio-culturaleIntrahepatic bile ductsSettore MED/42 - Igiene Generale E Applicataliver cancerhepatocellular carcinoma (HCC)SDG 3 - Good Health and Well-beingInternal medicinemedicinecancer registryeducationSupervivènciaeducation.field_of_studybusiness.industryFetge -- Càncer -- EstadístiquesCancerGeneral MedicineLiver -- Cancer -- Statisticsmedicine.diseasetrendInvasive Malignant NeoplasmHepatocellular carcinomainternational/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingLiver cancerbusinesscholangiocarcinomaSurvival trends liver cancer hepatocellular carcinoma (HCC) cholangiocarcinoma cancer registry international
researchProduct

El impacto de la inmunosupresión precoz en las complicaciones no asociadas al injerto hepático

2018

La falta de mejora a largo plazo de los resultados post-TH se debe en gran medida a complicaciones no asociadas al injerto en principio muy relacionadas con la exposición crónica a IS. En diferentes estudios se ha demostrado como la minimización de los ICN tiene un efecto protector en términos de toxicidad renal, metabólica, cardíaca y oncogénica. Sin embargo, no existe una evidencia sólida sobre el impacto que pueda tener la IS precoz, es decir aquella administrada en el post-trasplante inicial, y el desarrollo de dichas complicaciones. El grupo de Rodríguez-Perálvarez ha demostrado que tanto los niveles de Tac mayores de 10 ng/mL durante los primeros 15 días post-TH como la presencia de p…

tumores de novoinsuficiencia renalresultados a largo plazotrasplante hepáticoeventos cardiovascularesUNESCO::CIENCIAS MÉDICASmortalidadinmunosupresión:CIENCIAS MÉDICAS [UNESCO]recurrencia carcinoma hepatocelular
researchProduct

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

2020

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

unstable anginaMyocardial ischaemia[SDV]Life Sciences [q-bio]Vascular damage Radboud Institute for Health Sciences [Radboudumc 16]dual antithrombotic therapyGuidelineheparin030204 cardiovascular system & hematologyPlatelet inhibitionantiplatelet0302 clinical medicineST segmentMedicinedabigatranMyocardial infarctionguidelinesglycoprotein iib/iiia inhibitorsanticoagulationNon-ST Elevated Myocardial InfarctionrivaroxabanComputingMilieux_MISCELLANEOUSreproductive and urinary physiologydiabetesbleedingsbivalirudinatherothrombosiDisease ManagementangioplastyGuidelines • acute cardiac care • acute coronary syndrome • angioplasty • anticoagulation • antiplatelet • apixaban • aspirin • atherothrombosis • betablockers • bleedings • bivalirudin • bypass surgery • cangrelor • chest pain unit • clopidogrel • dabigatran • diabetes • dual antithrombotic therapy • early invasive strategy • edoxaban • enoxaparin • European Society of Cardiology • fondaparinux • glycoprotein IIb/ IIIa inhibitors • heparin • high-sensitivity troponin • minoca • myocardial ischaemia • myocardial infarction • nitrates • non-ST-elevation myocardial infarction • platelet inhibition • prasugrel • recommendations • revascularization • rhythm monitoring • rivaroxaban • stent • ticagrelor • triple therapy • unstable anginaenoxaparinGeneral MedicineClopidogrel3. Good healthearly invasive strategymyocardial infarctiontriple therapy030220 oncology & carcinogenesisHigh sensitivity troponinembryonic structuresCardiologyPlatelet aggregation inhibitorrevascularizationbiological phenomena cell phenomena and immunityCardiology and Cardiovascular MedicineTicagrelormedicine.drugHumanrecommendationAcute coronary syndromemedicine.medical_specialtyaspiringlycoprotein IIb/IIIa inhibitornon-ST-elevation myocardial infarctionapixabanrhythm monitoringEuropean Society of Cardiologyticagrelor03 medical and health sciencesnitrateatherothrombosisbetablockersInternal medicineacute cardiac careminocachest pain unitDiseases of the circulatory (Cardiovascular) systemHumansIn patientAcute Coronary SyndromeclopidogrelUnstable anginaurogenital systemnitratesbusiness.industryfondaparinuxbetablockerArrhythmias Cardiac030229 sport sciencesbleedingmedicine.diseasemyocardial ischaemiaplatelet inhibitionprasugreldiabeteGlycoprotein IIb/IIIa inhibitorsRC666-701bypass surgerySettore MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARErecommendationsedoxabanhigh-sensitivity troponinstentbusinessPlatelet Aggregation Inhibitorscangrelor
researchProduct

Real-world experience with obeticholic acid in patients with primary biliary cholangitis

2021

Background & aims Obeticholic acid (OCA) is the second-line treatment approved for patients with primary biliary cholangitis (PBC) and an inadequate response or intolerance to ursodeoxycholic acid. We aimed to evaluate the effectiveness and safety of OCA under real-world conditions. Methods Patients were recruited into the Italian PBC Registry, a multicentre, observational cohort study that monitors patients with PBC at national level. The primary endpoint was the biochemical response according to Poise criteria; the secondary endpoint was the biochemical response according to normal range criteria, defined as normal levels of bilirubin, alkaline phosphatase (ALP), and alanine aminotransfer…

upper limit of normalCirrhosisALTAMAAutoimmunityantinuclear antibodiesULNPBCGastroenterologyUDCASettore MED/12ULN upper limit of normalobeticholic acidaRR adjusted risk ratio.CRFs case record formAST aspartate transferaseClinical endpointGGT gamma-glutamyl transferaseQCprimary biliary cholangitisGastroenterologyUrsodeoxycholic acidANATCCCirrhosisCholestasiTIPSTreatment Completer CohortANA antinuclear antibodiemedicine.medical_specialtyRRUDCA ursodeoxycholic acidTIPS transjugular intrahepatic portosystemic shuntOCACirrhosiALP alkaline phosphataseautoimmune hepatitismedicine.diseasedigestive system diseasesDiscontinuationKeywords: AIH autoimmune hepatitiQC quality controlchemistrygamma-glutamyl transferaserandomised controlled trialelectronic data captureantimitochondrial antibodiesaspartate transferaseAutoimmune hepatitischemistry.chemical_compoundAIHCRFsImmunology and Allergyadjusted risk ratioANA antinuclear antibodiesRR risk ratioOverall cohortALT alanine transferaseAMA antimitochondrial antibodieCholestasisCRFs case record formsObeticholic acidOverlap PBC-AIHursodeoxycholic acidOCA obeticholic acidTolerabilityalkaline phosphataseRCTResearch Articlemedicine.drugcase record formsContext (language use)AMA antimitochondrial antibodiesInternal medicineEDC electronic data capturetransjugular intrahepatic portosystemic shuntInternal MedicinemedicineRCT randomised controlled trialaRR adjusted risk ratioOClcsh:RC799-869quality controlalanine transferaseASTaRRHepatologybusiness.industryAutoimmunity; Cholestasis; Cirrhosis; Overlap PBC-AIHAIH autoimmune hepatitisTCC Treatment Completer CohortPBC primary biliary cholangitiGGTrisk ratioOC Overall cohortALPlcsh:Diseases of the digestive system. GastroenterologyPBC primary biliary cholangitisbusinessEDC
researchProduct

Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus

2019

Background. Management of venous thromboembolism (VTE) in patients with haematologic malignancies and thrombocytopenia is clinically challenging due to the related risks. No prospective studies or clinical trials have been carried out and, therefore, no solid evidence on this compelling issue is available. Methods. Given this, an expert panel endorsed by the Gruppo Italiano Malattie Ematologiche dell'Adulto Working Party on Thrombosis and Haemostasis was set up to produce a formal consensus, according to the RAND method, in order to issue clinical recommendations about the platelet (PLT) cut-off for safe administration of low molecular weight heparin (LMWH) in thrombocytopenic (PLT <100×…

venous thrombosis thrombocytopenia blood cancer anticoagulant treatment consensusanticoagulantsblood cancerblood plateletsvenous thromboembolismthrombocytopeniaHeparin Low-Molecular-Weightheparinplatelet countanticoagulant treatmentSettore MED/15 - MALATTIE DEL SANGUEVenous thromboembolism haematological malignancythrombocytopeniaconsensuslow-molecular-weightOriginal Articlehematologic neoplasmscardiovascular diseasesvenous thrombosishumansanticoagulant treatment; blood cancer; consensus; thrombocytopenia; venous thrombosis; anticoagulants; blood platelets; heparin low-molecular-weight; humans; platelet count; consensus; hematologic neoplasms; thrombocytopenia; venous thromboembolismAnticoagulant treatment; Blood cancer; Consensus; Thrombocytopenia; Venous thrombosis
researchProduct

Predominance of Type 1 Innate Lymphoid Cells in the Rectal Mucosa of Patients With Non-Celiac Wheat Sensitivity: Reversal After a Wheat-Free Diet.

2016

OBJECTIVES: Non-celiac wheat sensitivity (NCWS) is defined as a reaction to ingested wheat after exclusion of celiac disease and wheat allergy. As its pathogenesis is incompletely understood, we evaluated the inflammatory response in the rectal mucosa of patients with well-defined NCWS. METHODS: The prospective study included 22 patients with irritable bowel syndrome (IBS)-like clinical presentation, diagnosed with NCWS by double-blind placebo-controlled challenge. Eight IBS patients not improving on wheat-free diet were used as controls. Two weeks after oral challenge was performed with 80 grams of wheat daily, cells were isolated from rectal biopsies and thoroughly characterized by fluore…

wheat-free diet.0301 basic medicineNon-Celiac Wheat SensitivityPathologymedicine.medical_specialtyWheat free dietSettore MED/09 - Medicina Internabusiness.industryOriginal ContributionsInnate lymphoid cellGastroenterologyfood and beveragesType 1 Innate Lymphoid Cell03 medical and health sciences030104 developmental biology0302 clinical medicineRectal mucosaRectal MucosaImmunologyMedicine030211 gastroenterology & hepatologybusinessType 1 Innate Lymphoid Cells; Rectal Mucosa; Non-Celiac Wheat Sensitivity
researchProduct

Hroniska C hepatīta ārstēšanas efektivitāte ar tiešās darbības antivirālajiem medikamentiem: reālas dzīves dati

2017

Darba aktualitāte: Hronisks C hepatīts ir globāla problēma jau daudzus gadus. Slimības sākuma stadijā parasti nav simptomu. Pēdējo dažu gadu laikā hroniska C hepatīta ārstēšana ir būtiski izmainījusies un ar jauno medikamentu palīdzību ir iespēja pilnībā izārstēties. Jaunais ārstēšanas kurss ir īsāks, labi panesams un ir augsta efektivitāte. Darba mērkis: Izvērtēt tiešās darbības antivirālo medikamentu efektivitāti un ieguvumus Latvijā. Metodes un materiāli: Tika veikts retrospektīvs pētījums, apkopota informācija no pacientu ambulatorajām kartēm, kuras tika ņemtas no Latvijas Infektoloģijas centra. Pētījumam tik atlasīti pacienti, kuriem ir diagnoze “Hronisks C hepatīts” un kuri ārstēšanā …

ģenēriskie medikamentitiešās darbības antivirālie medikamentiHronisks C hepatītsnoturīga virusoloģiskā atbildeMedicīna
researchProduct